KAMPOS
19.5.2020 07:02:04 CEST | Business Wire | Press release
KAMPOS , an Italian startup company, today announced the launch of a socially-responsible, environmentally friendly line of products and accessories to celebrate the history and beauty of the Mediterranean Sea. Founded by entrepreneur Alessandro Vergano, KAMPOS’ corporate vision is to “offer luxury products with a conscience, now and for generations to come.” All products are made of recycled plastic bottles, abandoned “ghost” fishing nets, or other recycled nylon and/or organic fabrics. Every product and accessory detail have been studied and designed to be sustainable. KAMPOS’ products are recycled AND are recyclable after use.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200518005003/en/
“Fashion companies have a tremendous platform from which to reach consumers in a positive manner, but few have embraced social issues as part of their business model,” said Vergano, KAMPOS’ co-founder and chief executive officer. “KAMPOS is different in that sustainability is at the core of everything we do from the selection from raw materials to product development to packaging. This means consumers will realize long-lasting performance of the products in which they invest because of enhanced durability and will be acting in a socially responsible manner with each purchase.”
Vergano’s vision for KAMPOS is to raise awareness worldwide of the impact of plastic pollution and abandoned fishing nets by offering sustainable, alternative high fashion solutions for consumers who share in the company’s mission. A percentage of KAMPOS’ revenues will be donated One Ocean Foundation (https://www.1ocean.org/en/ ), a non-profit founded in Porto Cervo, Sardinia. The joint effort is to accelerate solutions to ocean issues promoting a sustainable blue economy and enhancing knowledge through ocean literacy.
KAMPOS’ initial product line, which is all made in Italy, consists of swimsuits, shirts, t-shirts, perfumes, sunglasses, pareos (wraparounds) and accessories for men, women, and children. The company’s products are made of: Econyl, 100% regenerated nylon (filament) or certified GOTS (Global Organic Textile Standard) organic and biological cotton; and Newlife™, a unique, certified system of recycled polyester filament yarns that are 100% post-consumer bottle sourced, processed into a polymer through a mechanical -- not chemical -- process, and spun into yarn. No plastic is used in the packaging. The product line is now officially online at www.kampos.com and will be available for purchase in May. In June, KAMPOS plans to open its initial store in Porto Cervo, Sardinia (Italy) at the prestigious Promenade Du Port.
The name KAMPOS is an abbreviation of the Greek word HIPPO KAMPOS, which translates into Seahorse. In Rome and Greek cultures, the Seahorse was sacred to Neptune and Poseidon, the Sea Gods. It was considered a symbol of power, authority and good fortune with strong emotions and intuitions. Vergano launched KAMPOS in homage to his heritage and to celebrate the Mediterranean lifestyle.
KAMPOS’ innovative luxury fashion line includes active involvement from some of Italy’s more prominent creative and photography talent including the Carla Pozzi Agency and Art Director Roberto Da Pozzo in Milan. Additional information about KAMPOS, its products and accessories, are available on Pinterest , Instagram , Facebook and YouTube .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200518005003/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the
Helical Fusion Named a Final Candidate for Japan’s METI Fusion Power Demonstration Program1.9.2026 04:00:00 CEST | Press release
Milestone-based government program supports multiple fusion approaches toward power demonstration and commercialization Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator toward commercially viable fusion power, has been named a final candidate for Japan’s Ministry of Economy, Trade and Industry (METI) program supporting the demonstration of fusion power generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831991676/en/ Image of Helix HARUKA, Helical Fusion’s Integrated Demo Device(left), and Helix KANATA, Helical Fusion’s Fusion Pilot Plant(right) The program is designed to accelerate fusion power demonstration in the 2030s under Japan’s national energy and fusion strategies. It supports private-sector technology development across multiple fusion approaches, including tokamak, stellarator and laser fusion, with approximately JPY 60 billion in total government support anticipated ove
Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28[1]31.8.2026 23:35:00 CEST | Press release
ITC Infotech Board approves proposed acquisition of 22.1% promoter stake and a Scheme of Amalgamation of the two companies ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will syner
Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 21:07:00 CEST | Press release
Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 21:00:00 CEST | Press release
Agreement advances patient access and strengthens BeOne's long-term commitment to U.S. innovation and manufacturing BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional res
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom